Brics Diabetes Drugs Market

The BRICS Diabetes Drugs Market value is projected to reach USD 97.56 Bn. at the end of the forecast period and it is expected to grow at the CAGR of 12.2%.

BRICS Diabetes Drugs Market Overview:

Diabetes drugs are the medications that are used to treat diabetes mellitus type-1 and type-2 by dropping the blood glucose level of the body. There are various classes of drugs involved in the treatment of diabetes which is administered by oral route, intravenous, and subcutaneous routes. The increasing occurrence of diabetes, particularly type-2 diabetes, and the increasing demand for effective drug therapies for the treatment of diabetes are some of the factors expected to boost the diabetes drug market during the forecast period (2024-2030). Recent research analyses that metformin a common, generic type-2 diabetes medication used to manage blood sugar levels is associated with significantly lower COVID-19 death risk in women, but not in men.To know about the Research Methodology :- Request Free Sample Report

The occurrence of diabetes is going up across the globe, because of increased life expectancy, shifting eating styles of individuals, and the rising incidence of obesity. Brazil’s diabetes drug market is witnessing a double-digit growth rate, while the Russian insulin market is also expected to show significant growth with a predictable 25 million patients in this region requiring diabetes treatment by 2030.

BRICS Diabetes Drugs Market Country Analysis:

India and China have the highest number of diabetics in the globe, as China is expected to have above 72 million diabetic patients by 2030 and also huge patient base in India has already focused on several pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to hold the market share in the Indian market for diabetes drugs. Therefore, the diabetes drug market in BRIC economies is expected to create significant growth opportunities in the future.

BRIC countries hold a significant market share of the global market for diabetes drugs as they together account for 38% of the global occurrence of diabetes conditions. Because of improvements in living standards, the rising incidence of diabetes in BRIC is expected to closely 100 million patients by 2030, or about 40% of the world’s diabetic population.

The slowdown of the pharma market growth in developed economies has focused investor interest on BRIC countries, where the diabetes drug market has promoted significantly from government initiatives for spreading patient awareness, and the subsequent increase in the approval of novel drugs such as incretin mimetics (Eli Lilly’s Byetta) and dipeptidyl inhibitors (Merck’s Januvia and Novartis’ Galvus).

The report focuses on diabetes drugs market value at the BRICS countries of the world, which shows a countrywise development, including market size, share, revenue, and much more across the BRICS countries. The report has covered, capacity, production value, cost/profit, and supply/demand by statistical analysis. A brief analysis of drivers, restraints, opportunities, and challenges in the market is also covered with examples by countries. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. It also has covered the analysis of key player’s growth strategies, micro and macro analysis of markets, key developments, and key trends in the market.

BRICS Diabetes Drugs Market Scope: Inquire before buying

BRICS Diabetes Drugs Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

BRICS Diabetes Drugs Market Key Players

1.Abbott Laboratories
2.Aurobindo Pharma Ltd
3.Bayer Healthcare Ag
4.Biocon Ltd
5.Boehringer Ingelheim
6.Bristol-Myers Squibb
7.Dr. Reddy's Laboratories Ltd
8.Eli Lilly And Company
9.Glenmark Pharmaceuticals Ltd
10.Glaxosmithkline Plc
11.Lupin Ltd
12.Merck & Co. Inc.
13.Novo Nordisk A/S
14.Piramal Healthcare Ltd
15.Ranbaxy Laboratories Ltd
16.Roche Holding Ltd
17.Sanofi-Aventis
18.Shreya Life Sciences Pvt Ltd
19.Sun Pharma Industries Ltd
20.Takeda Pharmaceuticals Company
21.Zydus Cadila Healthcare Ltd
22.Medtronic
23.AstraZeneca Plc.
24.Lifescan
25.Terumo Medical Corporation

Frequently Asked Questions:

1. Which region has the largest share in Global Diabetes Drugs Market?
Ans: Asia Pacific region held the highest share in 2023.

2. What is the growth rate of Global Diabetes Drugs Market?
Ans: The Global Diabetes Drugs Market is growing at a CAGR of 12.2% during forecasting period 2024-2030.

3. What is scope of the Global Diabetes Drugs market report?
Ans: Global Diabetes Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Diabetes Drugs market?
Ans: The important key players in the Global Diabetes Drugs Market are – Dr. Reddy's Laboratories Ltd, Eli Lilly And Company, Glenmark Pharmaceuticals Ltd, Glaxosmithkline Plc, Lupin Ltd, Merck & Co. Inc., Novo Nordisk A/S, Piramal Healthcare Ltd, Ranbaxy Laboratories Ltd, Roche Holding Ltd, Sanofi-Aventis, Shreya Life Sciences Pvt Ltd, Sun Pharma Industries Ltd, Takeda Pharmaceuticals Company, Zydus Cadila Healthcare Ltd, Medtronic, AstraZeneca Plc., Lifescan, and Terumo Medical Corporation

5. What is the study period of this market?
Ans: The Global Diabetes Drugs Market is studied from 2023 to 2030.